AstraZeneca’s drug candidate baxdrostat lowered systolic blood pressure in a phase 3 clinical trial involving patients with uncontrolled or treatment-resistant hypertension.
In the trial, patients who received either 1 mg or 2 mg of baxdrostat once daily had a greater reduction in mean seated systolic blood pressure after 12 weeks compared with those who received a placebo, according to a July 14 news release from the drugmaker.
Participants continued their existing antihypertensive treatments during the study, the release said.
AstraZeneca said it will share data with regulators and present results from the study at the European Society of Cardiology Congress in August.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.